Published in Blood on January 01, 1994
BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A (1996) 3.10
Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A (1997) 2.82
Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev (1998) 2.23
Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med (1997) 2.17
Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A (1995) 2.13
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J (1995) 1.94
Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching. Mol Cell Biol (1999) 1.91
Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product. Mol Cell Biol (2000) 1.77
Retracted The BTB domain of bric à brac mediates dimerization in vitro. Mol Cell Biol (1995) 1.38
BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. J Exp Med (2003) 1.36
BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor. Mol Cell Biol (1998) 1.29
Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol (1995) 1.24
A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells. Am J Pathol (1995) 1.07
BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer (2009) 0.98
Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol (1996) 0.97
Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol (2004) 0.96
The cat immunoglobulin lambda light chain gene maps to chromosome D3p12-p11. Mamm Genome (1998) 0.78
Role of the Transcriptional Repressor BCL6 in Allergic Response and Inflammation. World Allergy Organ J (2008) 0.77
Analysis of follicular lymphoma by dual-color fluorescence in situ hybridization. Virchows Arch (2007) 0.76
trans repression of the human metallothionein IIA gene promoter by PZ120, a novel 120-kilodalton zinc finger protein. Mol Cell Biol (1999) 0.76
Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol (2002) 0.75
Sleep patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol (2000) 2.49
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost (2006) 2.40
Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med (1997) 2.17
Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem (1976) 2.07
Infantile acute subdural hematoma. Clinical analysis of 26 cases. J Neurosurg (1984) 1.96
p27/Kip1 mutation found in breast cancer. Cancer Res (1996) 1.94
Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest (1978) 1.79
The transcondylar approach to extradural nonneoplastic lesions of the craniovertebral junction. J Neurosurg (1996) 1.74
A test of significance for geographic clusters of disease. Int J Epidemiol (1979) 1.68
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest (1980) 1.58
Mediation of cardioprotection by transforming growth factor-beta. Science (1990) 1.52
Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem (1994) 1.50
Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur Heart J (2001) 1.49
Cardiac metastasis of lung cancer. A study of metastatic pathways and clinical manifestations. Cancer (1992) 1.44
Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest (1979) 1.43
Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood (1995) 1.42
A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin. J Pharmacol Exp Ther (1978) 1.42
A novel mutation that leads to a congenital factor XI deficiency in a Japanese family. Am J Hematol (2000) 1.39
Communicating triventricular hydrocephalus and its treatment with a lumboperitoneal shunt. Neurosurgery (1985) 1.37
Antithrombin 3 depression and thrombin generation acceleration in women taking oral contraceptives. Am J Obstet Gynecol (1971) 1.34
The behavior of alpha2-plasmin inhibitor in fibrinolytic states. J Clin Invest (1977) 1.31
Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation (1990) 1.31
Dlk1 in normal and abnormal hematopoiesis. Leukemia (2005) 1.28
Lactation-dependent expression of an mRNA splice variant with an exon for a multiply O-glycosylated domain of mouse milk fat globule glycoprotein MFG-E8. Biochem Biophys Res Commun (1999) 1.27
Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor. J Biol Chem (1994) 1.25
Plasma thrombomodulin in health and diseases. Blood (1990) 1.24
Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest (1982) 1.22
Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas. J Virol (1987) 1.21
Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood (1994) 1.20
Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res (1999) 1.17
Chronic encapsulated intracerebellar hematoma in infancy: case report. Neurosurgery (1984) 1.17
Recognition DNA sequence of a novel putative transcription factor, BCL6. Biochem Biophys Res Commun (1994) 1.16
Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood (1994) 1.16
Studies on suppressor cell function in thyroid diseases. J Clin Endocrinol Metab (1979) 1.16
Pancreatic cancer with metastasis to the larynx. J Laryngol Otol (1980) 1.16
The wide distribution of endornaviruses, large double-stranded RNA replicons with plasmid-like properties. Arch Virol (2005) 1.15
Hepadnaviruses in cirrhotic liver and hepatocellular carcinoma. J Med Virol (1990) 1.15
Carboxy-terminal cytoplasmic domain of mouse butyrophilin specifically associates with a 150-kDa protein of mammary epithelial cells and milk fat globule membrane. Biochim Biophys Acta (1995) 1.15
Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. Food Chem Toxicol (2002) 1.14
Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridization analysis. Neurosci Lett (1992) 1.13
Critical role of calcium- dependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling. J Biol Chem (1997) 1.11
Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene (2006) 1.09
The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta (1978) 1.09
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene (2012) 1.08
Characterization of the promoter region of the human c-kit proto-oncogene. Jpn J Cancer Res (1993) 1.08
Antisense expression of a rice sucrose transporter OsSUT1 in rice (Oryza sativa L.). Plant Cell Physiol (2001) 1.08
Distribution of cold-insoluble globulin in plasma and tissues. Ann N Y Acad Sci (1978) 1.07
Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J (2000) 1.07
Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol (1997) 1.06
Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin. Thromb Haemost (1978) 1.06
JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation (2001) 1.06
Sensitive spectrophotometric method for the determination of ethylenediaminetetraacetic acid in foods. Analyst (1993) 1.05
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother (2007) 1.05
Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr (2007) 1.05
A 33-kDa allergen from rice (Oryza sativa L. Japonica). cDNA cloning, expression, and identification as a novel glyoxalase I. J Biol Chem (2001) 1.04
Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol (1994) 1.04
Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc Natl Acad Sci U S A (1979) 1.03
Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin Endocrinol (Oxf) (2000) 1.03
Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem (1982) 1.02
Mucoepidermoid carcinoma of the thymic region. Acta Pathol Jpn (1982) 1.01
The effect of K + on the membrane potential in HeLa cells. Biochim Biophys Acta (1973) 1.01
Alterations of the p15, p16,and p18 genes in osteosarcoma. Cancer Genet Cytogenet (1996) 1.01
Human genes for complement components C1r and C1s in a close tail-to-tail arrangement. Proc Natl Acad Sci U S A (1988) 1.01
Increase of T cells in Graves' disease. Lancet (1973) 1.01
Air in acute epidural hematomas. Report of two cases. J Neurosurg (1986) 1.00
Functional characterization of the 5'-regulatory region of human factor IX gene. J Biol Chem (1990) 1.00
Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost (1984) 1.00
DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene (2007) 0.99
Bilateral chronic subdural hematomas associated with intracranial hypotension--case report. Neurol Med Chir (Tokyo) (1996) 0.99
Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol (1995) 0.99
The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene (1999) 0.98
The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Am J Clin Pathol (1971) 0.98
Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene (2000) 0.98
Anti-shock effects of human superoxide dismutase in splanchnic artery occlusion (SAO) shock. Proc Soc Exp Biol Med (1988) 0.97
Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta (1981) 0.97
Expanding intracerebellar hematoma: a possible clinicopathological entity. Neurosurgery (1986) 0.97
A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol (1997) 0.96
Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol (2001) 0.96
Natural inhibitors of fibrinolysis. Prog Cardiovasc Dis (1979) 0.96
Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias. Blood (1994) 0.95
Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4. Cytogenet Cell Genet (1989) 0.95
Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. Blood (1978) 0.94
Molecular analysis of a novel protein kinase in maturing rice seed. Gene (1998) 0.94
Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem (1986) 0.94
Study on anti-androgenic effects of bisphenol a diglycidyl ether (BADGE), bisphenol F diglycidyl ether (BFDGE) and their derivatives using cells stably transfected with human androgen receptor, AR-EcoScreen. Food Chem Toxicol (2004) 0.94
Human serum plasminogen antiactivator: its distinction from antiplasmin. Am J Physiol (1971) 0.94
Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett (1983) 0.94
Dissimilarity of human vascular plasminogen activator and human urokinase. J Lab Clin Med (1971) 0.94
Retracted Molecular cloning and characterization of a novel dual specificity phosphatase, LMW-DSP2, that lacks the cdc25 homology domain. J Biol Chem (2001) 0.94
Assay of alpha2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. Thromb Res (1978) 0.93